Advanced imaging plays a crucial role in the diagnosis and management of many pathological entities and is a pivotal component of clinical and translational research. One of the most prominent imaging tools at BRFAA is the non-invasive hybrid modality called Positron Emission Tomography/ Computed Tomography (PET/CT). This is highly versatile, as it makes it feasible to acquire and combine biological and morphological data. PET allows visualization, characterization, and measurement of biological processes at cellular, subcellular, and molecular levels in living subjects. This is achieved by using a range of radioactive tracers, the most common of which, is the glucose analogue 2-fluoro-2-deoxyglucose (FDG) labelled with fluorine-18 (18F). PET/CT has a broad spectrum of clinical applications in cancer, cardiovascular, neurological, inflammatory and infectious diseases and offers unique research possibilities.